Compare RFL & CNXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | CNXU |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.1M | 111.7M |
| IPO Year | 2017 | 2025 |
| Metric | RFL | CNXU |
|---|---|---|
| Price | $1.50 | $3.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 110.1K | ★ 163.1K |
| Earning Date | 10-28-2026 | 02-03-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $3.60 |
| 52 Week High | $3.96 | $13.66 |
| Indicator | RFL | CNXU |
|---|---|---|
| Relative Strength Index (RSI) | 22.43 | 29.51 |
| Support Level | $1.22 | N/A |
| Resistance Level | $1.37 | $5.47 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 3.70 | 2.97 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.